The Department of Justice and Drug Enforcement Administration issued a final order in late April 2026 that immediately moved FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act. This partial rescheduling followed a December 2025 executive order directing expedited federal action on cannabis reform. A new expedited administrative hearing to consider broader rescheduling of all marijuana to Schedule III is now scheduled to begin on June 29, 2026. These steps have advanced federal policy on medical access and research while leaving recreational marijuana under stricter controls, creating a clear near-term timeline for potential further changes.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert$758,572 Vol.
31. März 2026
30. Juni
1%
31. Dezember
24%
$758,572 Vol.
30. Juni
$337,166 Vol.
1%
31. Dezember
$156,524 Vol.
24%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Department of Justice and Drug Enforcement Administration issued a final order in late April 2026 that immediately moved FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act. This partial rescheduling followed a December 2025 executive order directing expedited federal action on cannabis reform. A new expedited administrative hearing to consider broader rescheduling of all marijuana to Schedule III is now scheduled to begin on June 29, 2026. These steps have advanced federal policy on medical access and research while leaving recreational marijuana under stricter controls, creating a clear near-term timeline for potential further changes.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Markt eröffnet: Feb 7, 2026, 5:04 PM ET
Volumen
$758,572Enddatum
31. März 2026Markt eröffnet
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Department of Justice and Drug Enforcement Administration issued a final order in late April 2026 that immediately moved FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act. This partial rescheduling followed a December 2025 executive order directing expedited federal action on cannabis reform. A new expedited administrative hearing to consider broader rescheduling of all marijuana to Schedule III is now scheduled to begin on June 29, 2026. These steps have advanced federal policy on medical access and research while leaving recreational marijuana under stricter controls, creating a clear near-term timeline for potential further changes.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volumen
$758,572Enddatum
31. März 2026Markt eröffnet
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The Department of Justice and Drug Enforcement Administration issued a final order in late April 2026 that immediately moved FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act. This partial rescheduling followed a December 2025 executive order directing expedited federal action on cannabis reform. A new expedited administrative hearing to consider broader rescheduling of all marijuana to Schedule III is now scheduled to begin on June 29, 2026. These steps have advanced federal policy on medical access and research while leaving recreational marijuana under stricter controls, creating a clear near-term timeline for potential further changes.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen